GleamWall
中文EN

CING Cingulate Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1862150 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-30.3%
TTM EPS YoY22.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-240.8%
ROA-151.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets26.2%
Debt / equity0.00x
Current ratio3.90x
Interest coverage-25.09x

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-27.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$2.91M$1.49M$2.18M$2.00M$2.85M$2.70M$2.22M$4.33M
SG&A expense$4.58M$3.93M$5.74M$3.58M$3.15M$1.95M$1.48M$1.88M
Operating income-$7.49M-$5.41M-$7.92M-$5.59M-$6.00M-$4.65M-$3.71M-$6.21M
Interest expense$184,659$236,375$348,315$283,499$194,444$213,711$209,671—
Pretax income-$7.73M-$5.87M-$9.31M-$6.27M-$7.34M-$4.98M-$3.85M-$6.23M
Net income-$7.73M-$5.87M-$9.31M-$6.27M-$7.34M-$4.98M-$3.85M-$6.23M
EBITDA-$7.44M-$5.32M-$7.80M-$5.46M-$5.89M-$4.50M-$3.54M-$6.05M
EPS (basic)-0.53-0.45-0.95—-1.35-1.14-1.06—
EPS (diluted)-0.53-0.45-0.95—-1.35-1.14-1.06—
Weighted avg. shares (diluted)14.55M13.19M9.78M—5.43M4.39M3.65M—
Banking
Net interest income-$171,056-$138,513-$528,267-$555,188-$572,228-$136,930-$96,784—
Balance sheet
Cash & equivalents$23.19M$28.40M$25.89M$10.95M$6.12M$8.90M$9.52M$12.21M
Current assets$25.32M$30.21M$27.91M$12.01M$7.43M$10.22M$10.50M$12.66M
PP&E, net$1.67M$1.63M$1.67M$1.73M$1.69M$1.80M$1.94M$2.10M
Total assets$28.15M$33.07M$30.86M$15.07M$10.52M$13.47M$12.47M$14.86M
Current liabilities$6.48M$8.63M$10.96M$10.31M$5.88M$6.73M$5.62M$4.97M
Total liabilities$7.38M$9.60M$12.00M$12.56M$7.05M$7.96M$6.54M$7.41M
Shareholders' equity$20.77M$23.47M$18.86M$2.51M$3.47M$5.51M$5.93M$7.46M
Shares outstanding14.76M13.89M11.91M7.25M5.98M4.89M3.83M3.40M
Cash flow statement
Operating cash flow-$7.38M-$5.90M-$6.91M-$3.60M-$4.24M-$4.80M-$4.61M-$4.08M
Capital expenditure$83,183$67,080$61,183$156,213$0——$198,462
Free cash flow-$7.47M-$5.97M-$6.97M-$3.75M-$4.24M——-$4.28M
Investing cash flow-$83,183-$67,080-$61,183-$156,213$0——-$198,462
Financing cash flow$2.25M$8.48M$21.91M$8.59M$1.46M$4.18M$1.92M$6.45M
Depreciation & amortization$46,718$98,243$121,185$121,832$106,782$146,989$165,291$160,302
Stock-based compensation$733,285$362,227$593,100$385,965$592,824$187,390$357,649$60,349

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.